ALNY241220C220000
- 33.20
- -26.12-44.03%
Alnylam Pharmaceuticals Newsroom
TD Cowen Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $371
Alnylam Pharmaceuticals Price Target Maintained With a $296.00/Share by Piper Sandler
ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study
TD Cowen Sticks to Its Buy Rating for Alnylam Pharma (ALNY)
Alnylam Pharmaceuticals Announces Interim Phase 1 Data of Nucresiran
Express News | Alnylam Announces Interim Phase 1 Data of Nucresiran (Aln-Ttrsc04) Showing Rapid Knockdown of Ttr That Is Sustained at Six Months Following a Single Dose
US MOVERS&SHAKERS Nov 11-Nov 15, 2024
Alnylam Downgraded at Wolfe on Doubts Over Amvuttra Growth
Alnylam Pharmaceuticals To Present At UBS Global Healthcare Conference; Webcast At 11:45 AM ET
The 3.7% Return This Week Takes Alnylam Pharmaceuticals' (NASDAQ:ALNY) Shareholders Five-year Gains to 202%
This Airbnb Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday
Wolfe Research Downgrades Alnylam Pharmaceuticals(ALNY.US) to Sell Rating, Announces Target Price $205
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
Express News | Alnylam Pharmaceuticals Inc : Leerink Partners Cuts Target Price to $178 From $180
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $400
Alnylam Pharma's Promising Pipeline and Strong Financials Justify Buy Rating and $400 Target
Express News | HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $400 Price Target
A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $275 to $371
Express News | Barclays Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $329